The politics and bio-ethics of regulatory trust: Case-studies of pharmaceuticals

Medicine, Health Care and Philosophy

Volumn 11, Issue 4, 2008, Pages 415-426

  Abraham, John ^a  

^a UNIVERSITY OF SUSSEX   (United Kingdom)

Author keywords

Acquiescent norms; CSM; EMEA; FDA; Investigative norms; Pharmaceutical industry

Indexed keywords

DOPAMINE UPTAKE INHIBITOR; NOMIFENSINE;

ARTICLE; CLINICAL TRIAL; DEPRESSION; DRUG INDUSTRY; ETHICS; GOVERNMENT REGULATION; HUMAN; INTERPERSONAL COMMUNICATION; LEGAL ASPECT; MEDICAL ETHICS; METHODOLOGY; ORGANIZATION AND MANAGEMENT; POLITICS; RISK ASSESSMENT; TRUST;

CLINICAL TRIALS AS TOPIC; DEPRESSIVE DISORDER; DISCLOSURE; DOPAMINE UPTAKE INHIBITORS; DRUG INDUSTRY; ETHICS, CLINICAL; GOVERNMENT REGULATION; HUMANS; NOMIFENSINE; POLITICS; RISK ASSESSMENT; TRUST;

EID: 57949092897     PISSN: 13867423     EISSN: 15728633     Source Type: Journal    
DOI: 10.1007/s11019-008-9155-x     Document Type: Article

References (63)

1. Abraham, J. 1995. Science, politics and the pharmaceutical industry. London: UCL.
2. Abraham, J. 2002. The pharmaceutical industry as political player. Lancet 360: 1498-1502.
3. Abraham, J., and C. Davis. 2005. A comparative analysis of drug safety withdrawals in the UK and the US: Implications for current regulatory thinking and policy. Social Science & Medicine 61(5): 881-892.
4. Abraham, J., and G. Lewis. 2000. Regulating medicines in Europe: Competition, expertise and public health. London: Routledge.
5. Abraham, J., and J. Sheppard. 1999. The therapeutic nightmare: The battle over the world's most controversial sleeping pill. London: Earthscan.
6. Anon. 1984a. Italian product suspensions. Scrip 862: 1.
7. Anon. 1984b. Glaxo discontinues Althesin. Scrip 882: 17.
8. Austin, T.R., J. Anderson, and J. Richardson. 1973. Bronchospasm following Althesin anaesthesia. British Medical Journal 2 (5867): 661.
9. Avery, A.F., and A. Evans. 1973. Reactions to Althesin. British Journal of Anaesthesia 45 (3): 301-303.
10. Barash, D. 1983. FDA memo of meeting with Hoescht-Roussel Pharmaceuticals, 12 January.
11. Beamish, F. 1979. Adverse response to Althesin. Anaesthesia 34 (7): 683-684.
12. BJCP. 1977. Nomifensine. British Journal of Clinical Pharmacology 4 (Suppl. 2).
13. Bodewitz, H., H. Buurma, and G.H. de Vries. 1987. Regulatory science and the social management of trust in medicine. In The social construction of technological systems, ed. W. Bijker, T. Hughes, and T. Pinch, 243-259. Cambridge, MA: MIT Press.
14. Clarke, R.S.J., J.W. Dundee, R.T. Garrett, G.K. McArdle, and J.A. Sutton. 1975. Adverse reactions to intravenous anaesthetics: A survey of 100 reports. British Journal of Anaesthesia 47: 575-585.
15. Code of Federal Regulations. 1992. CFR Part 314, Subpart H (Accelerated Approval of New Drugs for Serious or Life-Threatening Illnesses).
16. Collier, J. 1985. Licensing and provision of medicines in the UK: An appraisal. Lancet 2: 377-380.
17. Committee on Safety of Medicines. 1976. Current problems, 2 (August).
18. Committee on Safety of Medicines. 1979. Current problems, 4 (April).
19. Crowther, A.N. 1973. Bronchospasm following Althesin Anaesthesia. British Medical Journal 1: 775.
20. Delamothe, T. 1989. Drug watchdogs and the drug industry. British Medical Journal 299: 476.
21. Dinmore, P. 1979. Althesin sensitivity testing. Anaesthesia 34: 374-375.
22. Dundee, J.W., and R.S.J. Clarke. 1973. Adverse reactions to intravenous anaesthetics. British Journal of Anaesthesia 45: 304.
23. Edmond, G. (ed.). 2004. Expertise in regulation and law. Aldershot: Ashgate.
24. Ellenberg, S.S., and R. Temple. 2000. Placebo-controlled trials and active-control trials in the evaluation of new treatments: Part 2: Practical issues and specific cases. Annals of Internal Medicine 133 (6): 464-475.
25. Evans, J.M., and J.A.M. Keogh. 1977. Adverse reactions to intravenous anaesthetic induction agents. British Medical Journal 2: 735-736.
26. FDA. 1997. Modernisation Act, Section 506(b)(3) of the Food, Drug and Cosmetic Act (as amended by Section 112 of FDAMA).
27. Fisher, M.M. 1976. Severe histamine mediated reactions to Althesin. Anaesthesia and Intensive Care 4: 33-35.
28. Fisher, M.M. 1979. Sensitivity testing for Althesin. Anaesthesia 34: 906-907.
29. Fisher, M.M., and D.G. More. 1981. The epidemiology and clinical features of anaphylactic reactions in anaesthesia. Anaesthesia and Intensive Care 4: 97.
30. Fleming, T.R. 2005. Surrogate endpoints and FDA's accelerated approval process. Health Affairs 24: 67-78.
31. Gale, E.A.M. 2001. Lessons from the glitazones. Lancet 357: 1871-1874.
32. Garattini, S., and V. Bertele. 2001. Adjusting Europe's drug regulation to public health needs. Lancet 358: 66.
33. Glaxo. 1974-1976. Althesin Data Sheets.
34. Glaxo. 1977. Althesin Data Sheet.
35. Habermann, W. 1977. A review of controlled studies with nomifensine, performed outside the UK. British Journal of Clinical Pharmacology 4 (Suppl. 2): 237-242.
36. Hart, S.M. 1978. Reaction to Althesin. British Journal of Anaesthesia 50: 1169.
37. Healey, T.E.J. 1973. Bronchospasm following Althesin induction. The Lancet, ii: 975.
38. Hester, J.B. 1973. Reaction to Althesin. British Journal of Anaesthesia 45: 303.
39. Horton, J.N. 1973. Adverse reaction to Althesin. Anaesthesia 28: 182-183.
40. House of Commons. 1984. Althesin. Parliamentary Debates, Hansard, 61, 12 June, w. col., 461-462.
41. House of Commons. 2005a. Inquiry into the influence of the pharmaceutical industry. Health Select Committee Hearing, 13 January, Evidence 298.
42. House of Commons. 2005b. Inquiry into the influence of the pharmaceutical industry. Health Select Committee Report.
43. Jago, R.H., and J. Restall. 1978. Sensitivity testing for Althesin. Anaesthesia 33: 644-645.
44. Jasanoff, S. 1990. The fifth branch: Science advisers as policy-makers. Cambridge, MA: Harvard University Press.
45. Jenner, F.A. 1977. Some of the problems and difficulties associated with clinical studies of antidepressant agents. British Journal of Clinical Pharmacology 4 (Suppl. 2): 199-207.
46. Lee, H.: 1979. FDA review and evaluation of clinical data. Original NDA (Nomifensine), 14 September.
47. Lee, H. 1980. FDA review and evaluation of clinical data. NDA Resubmission (Nomifensine), 1 October.
48. Lee, H. 1981. FDA review and evaluation of clinical data. Addendum, NDA Resubmission (Nomifensine), 3 March.
49. Mehta, S. 1973. Anaphylactic reaction to Althesin. Anaesthesia 28: 669-672.
50. Mirowski, P., and R. Van Horn. 2005. The contract organisation and the commercialisation of scientific research. Social Studies of Science 35: 503-548.
51. Mitka, M. 2003. Acclererated approval scrutinized - Confirmatory phase 4 studies on new drugs languish. Journal of the American Medical Association 289: 3227-3229.
52. Nettleton, S., R. Burrows, and L. O'Malley. 2005. The mundane realities of the everyday lay use of the internet for health and their consequences for media convergence. Sociology of Health & Illness 27 (7): 972-992.
53. Nettleton, S., and G. Hanlon. 2006. Pathways to the doctor in the information age. In New technologies in health care, ed. A. Webster, 57-70. London: Palgrave.
54. Notcutt, W.G. 1973. Adverse reaction to Althesin. Anaesthesia 28: 673-674.
55. Official Journal of the European Union. 2004. OJ L 136 30.4.2004. Of the European Parliament and the Council, 31 March 2004. Laying down community procedures for the authorisation and supervision of medicinal products for human and veterinary use and for establishing a European medicines agency, 2004, para. 33.
56. Papworth, D.P. 1983. Adverse reactions to Althesin. British Journal of Anaesthesia 55: 256.
57. PDAC. 1981. Transcript, Psychopharmacological Drugs Advisory Committee Meeting, FDA, Rockville, Maryland, 3 December.
58. Roberts, T.G., and B.A. Chabner. 2004. Beyond fast track for drug approvals. New England Journal of Medicine 351: 502.
59. Scott, P.V. 1979. Sensitivity testing for Althesin. Anaesthesia 34: 86-87.
60. Taeuber, K. 1977. Comparison of nomifensine and placebo. British Journal of Clinical Pharmacology 4 (Suppl. 2): 209-214.
61. Temple, R., and S.S. Ellenberg. 2000. Placebo-controlled trials and active-control trials in the evaluation of new treatments: Part 1: Ethical and scientific issues. Annals of Internal Medicine 133 (6): 455-463.
62. Watt, J.M. 1975. Anaphylactic reactions after use of CT 1341 (Althesin). British Medical Journal 2: 205-206.
63. Whitwam, J.G. 1978. Adverse reactions to intravenous induction agents. British Journal of Anaesthesia 50: 677-687.